Brand Name | Zydelig |
Generic Name | Idelalisib |
Drug Class | PI3K Inhibitor |
Availability | Prescription |
Manufacturer | Gilead Sciences |
Indications | Ulcerative Colitis, Crohn's Disease |
Type | Tablet |
Doses | Oral: 150 mg twice daily (induction), 150 mg daily (maintenance) |
Route | Oral |
Side Effects | Diarrhea, nausea, fatigue, liver enzyme elevation, infections |
Interactions | PI3K inhibitor; avoid CYP3A inhibitors and monitor for infections |
Overdose | Liver toxicity, diarrhea, infection risk. |
Missed Dose | Take ASAP; skip if near next. |
Contraindications | Severe hepatic impairment, active TB or serious infections. |
Alternatives | Upadacitinib, Filgotinib |
Co-Pay Assistance Program | Available Rx |
Patient Assistance Program | Available |
Tofacitinib is used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis by inhibiting Janus kinase (JAK) enzymes involved in the inflammatory process.
Tofacitinib works by inhibiting JAK enzymes, which play a critical role in the signaling pathways of the immune system, thus reducing inflammation and tissue damage.
Common side effects include upper respiratory infections, headache, and high blood pressure. Serious side effects may include blood clots and infections.
Tofacitinib is taken orally in tablet form, typically once or twice a day, depending on the condition being treated and the prescribed dosage.
Yes, Tofacitinib may increase the risk of serious infections. It is important to monitor for signs of infection and contact your doctor if you experience any symptoms.
Tofacitinib should be used during pregnancy only if the benefits outweigh the risks. Discuss with your healthcare provider if you are pregnant or planning to become pregnant.
If you miss a dose, take it as soon as you remember unless it�s almost time for your next dose. Do not take two doses at once.
Tofacitinib may interact with other immunosuppressive medications, so it�s important to inform your doctor about all the medications you're taking.
It may take several weeks to months for Tofacitinib to show noticeable effects, particularly in conditions like rheumatoid arthritis and ulcerative colitis.
Tofacitinib has been shown to be effective in treating moderate to severe ulcerative colitis, helping to induce and maintain remission in many patients.
Related Conditions |
Related Blogs |
---|---|